APA-referens

Norsworthy, K. J., Ko, C., Lee, J. E., Liu, J., John, C. S., Przepiorka, D., . . . Pazdur, R. (2018). FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia. Oncologist.

Chicago-stil citat

Norsworthy, Kelly J., Chia‐Wen Ko, Jee Eun Lee, Jiang Liu, Christy S. John, Donna Przepiorka, Ann T. Farrell, och Richard Pazdur. "FDA Approval Summary: Mylotarg for Treatment of Patients With Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia." Oncologist 2018.

MLA-referens

Norsworthy, Kelly J., et al. "FDA Approval Summary: Mylotarg for Treatment of Patients With Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia." Oncologist 2018.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.